Medtronic initiated a recall on the devices in November after finding higher-than-expected rates of failure when the implantable SynchroMed II pumps were used with "unapproved drugs."
"Based on data from the firm’s Implantable Systems Performance Registry, the overall failure rate of the SynchroMed II pump at 78 months post implant is 2.4% when used to dispense approved drugs, and 7.0% when used to dispense unapproved drugs," according to the FDA notice. "The use of unapproved drugs can lead to intermittent or permanent pump motor stall and cessation of drug infusion."
Motor stalls can occur with either approved or unapproved drugs, the company noted, but occurred at much higher rates with unapproved drugs.
Medtronic is recommending that healthcare providers use the SynchroMed II only with drugs approved on the device’s labeling, according to the notice.
Patients most struggle with hope and sex after prostate cancer
Prostate cancer patients rated maintaining hope and sex after illness the top 2 most difficult things to deal with, according to a Canadian survey.